The JAK2 V617F revolution in myeloproliferative neoplasms.

Allele burden expansion in JAK2 V617F and CALR ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment
Zi Yun Ng, Laurane Cottin, Marine Demoy +16
HemaSphere31 Aug 2026Peer-reviewedCC BY 4.0Full textHuman geneticsHAL
High prevalence and immunophenotypic diversity of clonal T‑large granular lymphocytes in JAK2‑mutated myeloproliferative neoplasms.
Weixia Zhuang, Lisha Lu, Li Jiang +2
Annals of hematology28 Sep 2026Peer-reviewedCC BY-NC-NDFull textHuman geneticsEurope PMCPMC
Biopsy-Proven Hepatic Extramedullary Hematopoiesis With Chronic Portal Vein Thrombosis in JAK2 V617F-Positive Prefibrotic Myelofibrosis: Contributors to Noncirrhotic Portal Hypertension
Rowan Bandaranaike, Beth Rutland, Travis Rutland
ACG case reports journal1 Oct 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
FDX1 is associated with CALR abundance and JAK–STAT-related inflammatory signaling in myeloproliferative neoplasms
Diyaer Abuduaini, Diernu Simayi, Mihelayi Maimaiti +2
Frontiers in oncology16 Oct 2026Peer-reviewedCC BYFull textOncologyEurope PMC
Megakaryocytic proteomic signatures define myeloproliferative neoplasms
I. Raman, C. Bennett, S.-R. Pasricha +12
bioRxiv30 Oct 2026PreprintAll rights reservedFull textOncologybioRxiv

Cite

BibTeX

@article{tefferi2026jak2,
  title = {{The JAK2 V617F revolution in myeloproliferative neoplasms.}},
  author = {Ayalew Tefferi},
  journal = {Haematologica},
  year = {2026},
  month = nov,
  doi = {10.3324/haematol.2026.301902},
  url = {https://europepmc.org/article/MED/42968700},
  note = {CC BY-NC},
}

RIS

TY  - JOUR
TI  - The JAK2 V617F revolution in myeloproliferative neoplasms.
AU  - Ayalew Tefferi
PY  - 2026
DA  - 2026/11/01
JO  - Haematologica
DO  - 10.3324/haematol.2026.301902
UR  - https://europepmc.org/article/MED/42968700
SN  - 0390-6078
SN  - 1592-8721
ER  -

Related

Cite